Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
26,288,408
-
Share change
-
-1,058,540
-
Total reported value
-
$25,523,780
-
Put/Call ratio
-
0%
-
Price per share
-
$0.97
-
Number of holders
-
41
-
Value change
-
-$906,296
-
Number of buys
-
8
-
Number of sells
-
20
Institutional Holders of ALIGOS THERAPEUTICS INC - COM NEW (ALGS) as of Q2 2023
As of 30 Jun 2023,
ALIGOS THERAPEUTICS INC - COM NEW (ALGS) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,288,408 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Vivo Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Versant Venture Management, LLC, HHLR ADVISORS, LTD., BAKER BROS. ADVISORS LP, ADAGE CAPITAL PARTNERS GP, L.L.C., BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, and Newtyn Management, LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.